| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Lilly's Foundayo wins EMA panel backing for obesity and type 2 diabetes | ||
| Fr | OrbiMed raises $3bn to back global life science players | ||
| Fr | AstraZeneca and insitro forge $1.5bn AI-powered cardiometabolic partnership | ||
| Fr | Acta Pharmaceuticals raises $24m for Alzheimer's therapies | ||
| Fr | Transcripta Bio, Mayo Clinic join force on ALS therapies | ||
| Do | Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers | ||
| Do | Rare disease regulation reaches "inflection point" with new FDA framework | ||
| Do | QCi and INmune Bio partner to study XPro in Alzheimer's | ||
| Do | ImmunityBio's bladder cancer drug, Anktiva lands US label expansion | ||
| Do | Alentis and PinotBio partner to develop claudin-1 oncology ADCs | ||
| Mi | Zealand Pharma pens $1.2bn AI obesity drug discovery pact with Generate | ||
| Mi | MHRA homes in on personalised healthcare and tech in new 2030 strategy | ||
| Mi | Charles River partners with Magellan Stem Cells on cell therapy | ||
| Mi | Pfizer partners with Enodia Therapeutics in $500m drug deal | ||
| Di | Tremfya rescues J&J's immunology sales to fuel strong Q3 | ||
| Di | China's NMPA clears Foresee's Camcevi 42 mg for prostate cancer | ||
| Di | Southern Research secures NIH funding for drug testing hub | ||
| Mo | FDA approves Teva's monthly injection of olanzapine for schizophrenia | ||
| Mo | FDA approves Asahi Kasei's Hovilpri for refractory HSV | ||
| Mo | Perceptive, Nucleus partner to support radiopharmaceutical development | ||
| 09.10. | Big tech- and pharma-backed Iambic Therapeutics aims for $135m IPO | ||
| 09.10. | Roche's Tecentriq snags FDA label expansion in type of colon cancer | ||
| 09.10. | Bio-Techne opens GMP small molecule facility in Bristol, UK | ||
| 09.10. | Biohaven partners with Ono in $100m IgG degrader deal | ||
| 08.10. | Viatris makes foray into non-opioid pain space on $1.65bn Pacira buyout |